Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014 - 14/12/17
, Jipan Xie, MD, PhD b, Jin Wei, MS b, Wenxi Tang, MS b, Vivian Herrera, DDS c, Jacqueline B. Palmer, PharmD cAbstract |
Background |
The burden of advanced basal cell carcinoma (aBCC) is not fully understood.
Objective |
To compare BCC disease burden and treatment patterns for aBCC with those for non-aBCC.
Methods |
A retrospective, insurance claims–based study design was used. Adults with ≥2 claims associated with a BCC diagnosis (ICD-9-CM 173.x1) separated by ≥30 days on or after October 1, 2011, were classified as aBCC or non-aBCC by using an algorithm based on metastasis diagnosis, radiation therapy use, and medical oncologist/other specialist use. Non-aBCC and aBCC patients were matched 1:1 on the basis of age, sex, and region, and assigned the same index date (date of first qualifying diagnosis or event). Comparisons were made using Wilcoxon signed-rank (continuous variables) and McNemar's (categorical variables) tests.
Results |
In total, 847 matched aBCC/non-aBCC patient pairs were selected (mean age 75 years; 57% men; locally advanced BCC, n = 826; metastatic BCC, n = 21). During the 12-month study period following the index date, aBCC patients had a significantly higher mean Charlson Comorbidity Index (P = .0023), significantly higher mean numbers of outpatient/dermatologist/medical oncologist visits (all P < .0001), and significantly higher mean total/medical/inpatient/outpatient/BCC treatment costs (all P < .05).
Limitations |
This study only included information from a database on commercial insurance and Medicare claims. The algorithm criteria might have restricted patient numbers; data were not fully reflective of targeted therapy era.
Conclusions |
aBCC patients had a higher disease burden than non-aBCC patients. Cost differences were largely driven by higher BCC treatment costs, specifically radiation therapy.
Le texte complet de cet article est disponible en PDF.Key words : basal cell carcinoma, burden, costs, healthcare utilization, treatment
Abbreviations used : aBCC, FDA, ICD-9-CM, laBCC, mBCC, NMSC
Plan
| Dr Wei is currently affiliated with TKL Research, Rochelle Park, New Jersey. |
|
| Funding sources: Supported by Novartis Pharmaceuticals Corporation. |
|
| Conflicts of interest: Dr Migden has received honoraria for advisory boards from Eli Lilly, Genentech, and Novartis. Dr Xie and Ms Tang are full-time employees of Analysis Group. Ms Wei was a full-time employee of Analysis Group at the time the study was conducted. Drs Palmer and Herrera are full-time employees of Novartis. |
|
| Reprints not available from the authors. |
Vol 77 - N° 1
P. 55 - juillet 2017 Retour au numéro
Article précédent
- 25-Hydroxyvitamin-D3 serum modulation after use of sunbeds compliant with European Union standards: A randomized open observational controlled trial
- Benedikt Weber, Chantal C. Bachmann, Ralph Braun, Alison G. Abraham, Andreas L. Serra, Günther F.L. Hofbauer
- Racial disparities in the impact of chronic pruritus: A cross-sectional study on quality of life and resource utilization in United States veterans
- Fiona M. Shaw, Kevin Man Hin Luk, Kuang-Ho Chen, Glenda Wrenn, Suephy C. Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?